Information Provided By: 
Fly News Breaks for November 19, 2019
MDCO
Nov 19, 2019 | 08:29 EDT
Baird analyst Madhu Kumar said he has utter conviction that The Medicine's Co. inclisiran can disrupt cholesterol therapy. The analyst cited its results from the ORION-9/10/11 trial which was released and supported his thesis. He said the remaining question is whether the company can find an acquirer or partner to help launch inclisiran. Kumar reiterated his Outperform rating and $100 price target on The Medicine's Co. shares.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
